15 terminated. 15 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 15 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 3 | Terminated 3 |
Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis KYV-101, Standard lymphodepletion regimen - Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 3 | 2024-08-06 | 2026-08-31 |
| An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) HZN-825 - Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Terminated | Amgen | 174 | 2022-11-04 | 2026-01-05 |
| A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis HZN-825 BID, Placebo, HZN-825 QD - Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Terminated | Amgen | 301 | 2021-11-05 | 2026-03-20 |
| A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients Ixazomib - Systemic Sclerosis, Scleroderma | Phase 2 | Terminated | Michael M. Pham | 4 | 2021-04-28 | 2025-04-06 |
| Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis Belumosudil - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Kadmon, a Sanofi Company | 10 | 2021-03-03 | 2023-06-05 |
| A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) FCX-013, veledimex - Morphea, Scleroderma, Localized | Phase 1 / Phase 2 | Terminated | Castle Creek Biosciences, LLC. | 1 | 2019-12-18 | 2024-01-23 |
| KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Belumosudil (KD025), Placebo - System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Kadmon, a Sanofi Company | 36 | 2019-06-26 | 2023-08-30 |
| Cardiac Safe Transplants for Systemic Sclerosis Rituximab, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Scleroderma | Phase 2 / Phase 3 | Terminated | Northwestern University | 9 | 2018-05-17 | 2020-08-12 |
| Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis JBT-101, Placebo, Part B Open-Label Extension - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Corbus Pharmaceuticals Inc. | 42 | 2015-08-01 | 2021-04-21 |
| Exparel as a Nerve Block for Severe Hand Pain liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease | Phase 2 / Phase 3 | Terminated | Jose Soberon, MD | 13 | 2014-11-01 | 2024-05-21 |
| A Clinical Trial for CTD-ILD Treatment N-Acetylcysteine - Interstitial Lung Disease, Connective Tissue Disease | Phase 2 / Phase 3 | Terminated | University of Michigan | 5 | 2011-12-01 | 2017-04-06 |
| Open-Label Study of Oral Treprostinil in Digital Ulcers treprostinil diethanolamine - Systemic Sclerosis | Phase 2 | Terminated | United Therapeutics | 115 | 2009-09-01 | 2024-06-18 |
| Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Imatinib mesylate, Placebo - Scleroderma | Phase 2 | Terminated | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 10 | 2008-04-01 | 2012-03-07 |
| Placebo Controlled Trial of Bosentan in Scleroderma Patients Bosentan, Placebo - Systemic Scleroderma, Pulmonary Hypertension | Phase 2 | Terminated | Georgetown University | 5 | 2006-09-01 | 2018-05-24 |
| Treatment of Early Systemic Sclerosis by Bosentan bosentan - Systemic Sclerosis (Scleroderma) | Phase 1 / Phase 2 | Terminated | Rikshospitalet University Hospital | 30 | 2005-01-01 | 2009-06-12 |
Scleroderma, Systemic (10) · Lung Diseases, Interstitial (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · CREST Syndrome (1) · Connective Tissue Diseases (1) · Dermatomyositis (1) · Fibrosis (1) · Hypertension, Pulmonary (1) · Mixed Connective Tissue Disease (1) · Peripheral Vascular Diseases (1) · Polymyositis (1) · Pulmonary Fibrosis (1) · Raynaud Disease (1)
Skin and Connective Tissue Diseases (15) · Connective Tissue Diseases (14) · Skin Diseases (14) · Scleroderma, Systemic (5) · Cardiovascular Diseases (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Immune System Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Vascular Diseases (2) · Arthritis (1) · Autoimmune Diseases (1) · Calcinosis (1) · Calcium Metabolism Disorders (1)
Bosentan (2) · Cyclophosphamide (2) · KD025 (2) · belumosudil (2) · fludarabine (2) · Acetylcysteine (1) · Antilymphocyte Serum (1) · Drug Delivery Systems (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Imatinib Mesylate (1) · Immunoglobulins, Intravenous (1) · Mesna (1) · Methylprednisolone (1) · Methylprednisolone Acetate (1)
Amgen (2) · Kadmon, a Sanofi Company (2) · Castle Creek Biosciences, LLC. (1) · Corbus Pharmaceuticals Inc. (1) · Georgetown University (1) · Jose Soberon, MD (1) · Kyverna Therapeutics (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Michael M. Pham (1) · Northwestern University (1) · Rikshospitalet University Hospital (1) · United Therapeutics (1) · University of Michigan (1)
United States (12) · Canada (2) · Serbia (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Chile (1) · Greece (1) · Israel (1) · Italy (1) · Japan (1) · Mexico (1) · Norway (1) · Poland (1) · Portugal (1)
James Seibold, MD (1) · Jan T Gran, Professor (1) · Janet E Pope, MD MPH FRCPC (1) · Jose Soberon, MD (1) · Michael Pham, MD (1) · Richard Burt, MD (1) · Robert Spiera, M.D. (1) · Virginia D Steen, MD (1)
PMID 24850877, PMID 32612255, PMID 40088930
2023 (1)